Novo Nordisk is turning to artificial intelligence to accelerate drug development, announcing a major partnership with OpenAI as competition intensifies in the booming weight-loss market.

Novo Nordisk is launching discounted subscription plans for its weight-loss drug Wegovy in the United States, as competition intensifies in the fast-growing obesity treatment market.

At least six Indian pharmaceutical companies have introduced low-cost versions of Novo Nordisk’s (Novo Nordisk) blockbuster diabetes drug Ozempic and weight-loss medication Wegovy over the weekend, offering treatment at prices up to 70% lower than the original.

Danish drugmaker Novo Nordisk plans to sell its obesity treatments through the platform of Hims & Hers Health, ending a dispute between the two firms that recently escalated into a legal battle.

Swiss pharmaceutical giant Roche is targeting a double-digit market share in the fast-growing global weight-loss drug sector, as it looks to narrow the gap with Danish rival Novo Nordisk.

Novo Nordisk announced Tuesday that its experimental obesity treatment UBT251, a triple agonist targeting the GLP-1, GIP and glucagon receptors, delivered a statistically significant mean weight loss of up to 19.7% after 24 weeks in a clinical trial.

Shares of Novo Nordisk plunged 15% on Monday after the company announced that its next-generation obesity drug failed to meet a key trial objective against a rival treatment from Eli Lilly.

Novo Nordisk said on Monday that its next-generation obesity treatment CagriSema proved less effective than tirzepatide, developed by Eli Lilly, in a head-to-head clinical trial — marking a setback in the competitive race for dominance in the fast-growing weight-loss drug market.

Novo Nordisk announced on February 20 that it will nominate Jan van de Winkel and Ramona Sequeira to its board of directors, marking the first board additions since a major shake-up at the Danish obesity drugmaker last year.